Literature DB >> 15885322

Evaluation of cerebrospinal fluid uPA, PAI-1, and soluble uPAR levels in HIV-infected patients.

B Sporer1, U Koedel, B Popp, R Paul, H-W Pfister.   

Abstract

To evaluate the potential role of the uPAR/uPA/PAI-1 system in HIV-induced blood-brain-barrier (BBB) disruption, CSF uPA-dependent plasminogen activation (PdPA) was analyzed by casein zymography, and CSF protein levels of all three molecules were measured by ELISA. CSF uPAR, but not uPA, PAI-1, or PdPA levels was significantly increased in neurologically compromised HIV+ patients. Only individual patients with severe AIDS dementia complex had increased levels of uPA (but not PAI-1) which fell upon initiation of antiretroviral therapy. The levels of all three molecules did not correlate with the CSF to serum albumin ratio suggesting not an important role in HIV-induced BBB disruption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15885322     DOI: 10.1016/j.jneuroim.2005.02.013

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia.

Authors:  Jimmi Nielsen; Rasmus Røge; Sofie Gry Pristed; Anne Grethe Viuff; Henrik Ullum; Lise Wegner Thørner; Thomas Werge; Torkel Vang
Journal:  Schizophr Bull       Date:  2014-08-25       Impact factor: 9.306

Review 2.  Adipokines and the blood-brain barrier.

Authors:  Weihong Pan; Abba J Kastin
Journal:  Peptides       Date:  2007-05-06       Impact factor: 3.750

3.  Plasma proteomic analysis of simian immunodeficiency virus infection of rhesus macaques.

Authors:  Jayme L Wiederin; Robert M Donahoe; James R Anderson; Fang Yu; Howard S Fox; Howard E Gendelman; Pawel S Ciborowski
Journal:  J Proteome Res       Date:  2010-09-03       Impact factor: 4.466

4.  Protein changes in CSF of HIV-infected patients: evidence for loss of neuroprotection.

Authors:  Rick B Meeker; Winona Poulton; Silva Markovic-Plese; Colin Hall; Kevin Robertson
Journal:  J Neurovirol       Date:  2011-05-10       Impact factor: 2.643

5.  Ligand-engaged urokinase-type plasminogen activator receptor and activation of the CD11b/CD18 integrin inhibit late events of HIV expression in monocytic cells.

Authors:  Massimo Alfano; Samanta A Mariani; Chiara Elia; Ruggero Pardi; Francesco Blasi; Guido Poli
Journal:  Blood       Date:  2008-10-21       Impact factor: 22.113

6.  Urokinase plasminogen activator inhibits HIV virion release from macrophage-differentiated chronically infected cells via activation of RhoA and PKCε.

Authors:  Francesca Graziano; Chiara Elia; Carlo Laudanna; Guido Poli; Massimo Alfano
Journal:  PLoS One       Date:  2011-08-17       Impact factor: 3.240

Review 7.  Relating GPI-Anchored Ly6 Proteins uPAR and CD59 to Viral Infection.

Authors:  Jingyou Yu; Vaibhav Murthy; Shan-Lu Liu
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

Review 8.  Modulation of Cellular Function by the Urokinase Receptor Signalling: A Mechanistic View.

Authors:  Daniela Alfano; Paola Franco; Maria Patrizia Stoppelli
Journal:  Front Cell Dev Biol       Date:  2022-04-08

9.  Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.

Authors:  Orla Cunningham; Suzanne Campion; V Hugh Perry; Carol Murray; Nicolai Sidenius; Fabian Docagne; Colm Cunningham
Journal:  Glia       Date:  2009-12       Impact factor: 7.452

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.